Given Imaging Announces National Coverage Policy from Aetna

ATLANTA, GA -- Given Imaging (NASDAQ:GIVN) announced today that Aetna has established a national coverage policy for the M2A capsule endoscope to investigate suspected small intestinal bleeding in patients with evidence of recurrent, obscure gastrointestinal bleeding who have had upper and lower gastrointestinal endoscopies that have failed to identify a bleeding source.

Aetna serves more than 13 million medical members bringing the number of Americans with reimbursable access to capsule endoscopy to 86 million Americans.

"We are encouraged that one of the largest and most respected payers in the country has recognized the clinical benefit and utility of capsule endoscopy for their members." said Gavriel D. Meron, President and CEO of Given Imaging. "We continue to gain momentum in reimbursement coverage and look forward to working with gastroenterologists to bring this effective diagnostic tool to the patients who need it."

Reimbursement is a Priority For Given Imaging
To assist medical professionals with insurance-related questions and coding issues, Given Imaging maintains a Reimbursement Helpline during normal business hours. The company also provides information on its website, including a list of payors who currently cover capsule endoscopy, as well as information related to Medicare reimbursement.

This press release contains forward-looking statements about Given Imaging, including projections about our business, our future revenues, and our future profitability, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. For example, statements in the future tense, words such as "anticipates," "estimates," "expects," "intends," "plans," "believes," and words and terms of similar substance used in connection with any discussion of future operating or financial performance identify such forward-looking statements. Those forward-looking statements are not guarantees of future performance and actual results could differ materially from our current expectations as a result of numerous factors, including but not limited to the following: changes in regulatory environment, our success in implementing our sales, marketing and manufacturing plan, protection and validity of patents and other intellectual property rights, the impact of currency exchange rates, the effect of competition by other companies, the outcome of future litigation, the reimbursement policies for our product from healthcare payors, quarterly variations in operating results, the possibility of armed conflict or civil or military unrest in Israel and other risks disclosed in our filings with the U.S. Securities Exchange Commission.

19.Sept.'03